Aggressive T-cell leukaemia treated with base-editing gene therapy
A 13-year old girl has received the first ever 'base-editing' therapy, in which cells were genetically modified to fight her otherwise incurable leukaemia...
A 13-year old girl has received the first ever 'base-editing' therapy, in which cells were genetically modified to fight her otherwise incurable leukaemia...
In this episode of The Life Scientific, Professor Balasubramanian speaks about the technology he discovered, alongside, Professor Sir David Klenerman, that has enabled scientists to sequence the human genome faster and cheaper than ever...
A novel gene therapy which uses base-editing to lower cholesterol has been given to the first patient in a clinical trial...
An approach which significantly improves the ability to modify mitochondrial DNA in living cells has been developed by scientists in South Korea...
The Centre for Bioethics and Harvard Medical School, Massachusetts, presented a fascinating talk on the opportunities for great medical advancements, and grave harm, presented to researchers by CRISPR/Cas9 and other apporaches to genome editing...
Splitting and reconstituting the enzymes used in the base editing method of genome editing may make more controlled changes possible...
Genome editing is a group of approaches that enable scientists to add, remove or alter selected DNA sequences at particular locations in the genome...
The mechanism underlying DNA damage that leads to melanoma has been found to be a specific mutation caused by UVB radiation in sunlight...
Base editing, a form of genome editing, has been used in preclinical model to correct a lysosomal storage disease known as Hurler syndrome...
This is something of a meta-review, as the podcast is purportedly a review of a book. The podcast is primarily a gently meandering discussion between journalist and author...
BioNews, published by the Progress Educational Trust (PET), provides news and comment on genetics, assisted conception, embryo/stem cell research and related areas.